Recruiting

Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers

retrospective/prospective observational study. Objective of the study is to evaluate the effect of drugs in terms of objective responses, disease-free survival (DFS), progression-free survival (PFS), overall survival (OS), and side effects compared with registry studies in the medical therapy of breast and gynecologic cancers.

ClinicalTrials.gov IDNCT06800612

PhaseNot Applicable

Enrollment100

SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

Age18 Years and older

SexALL

I'm interested View official listing

Conditions studied

Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic, Ovarian Cancer, Cervical Carcinoma, Endometrial Cancer

About this study

Interventions

Drug: Oncologic drugs administered for treatment of breast cancer — Data on oncologic drugs administered for treatment of breast cancer will be recorded
Drug: Oncologic drug administered for treatment of gynecologic cancer — Data on oncologic drugs administered for treatment of gynecologic cancer will be recorded

Primary outcomes

DFS (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months.)

Eligibility information

Inclusion Criteria: * Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic; * Patients who have received treatment for breast cancer or gynecologic cancer since January 2010; * Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data. Exclusion Criteria: * no exclusion criteria

Study locations

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138 Italy

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-08.